三种头孢吡肟/β-内酰胺酶抑制剂复方对产碳青霉烯酶肠杆菌的体外敏感性
该研究测定了2024年法国国家耐药参考中心6个月内收集的1600株产碳青霉烯酶肠杆菌对头孢吡肟-恩美唑巴坦、头孢吡肟-他尼硼巴坦和头孢吡肟-齐德巴坦的MIC,并进行全基因组测序分析。结果显示头孢吡肟-他尼硼巴坦对KPC、OXA-48-like和VIM生产者活性高,头孢吡肟-齐德巴坦对金属β-内酰胺酶活性最强,但已出现耐药克隆。
要点
- 头孢吡肟-恩美唑巴坦对OXA-48-like生产者敏感率90%,对KPC生产者仅54%。
- 头孢吡肟-他尼硼巴坦对KPC、OXA-48-like、VIM生产者敏感率分别为100%、95%、98%,对NDM为76%。
- 头孢吡肟-齐德巴坦对所有CPE类型活性强,但已出现NDM-14产K. pneumoniae ST-147耐药克隆。
核心结论
- 头孢吡肟-恩美唑巴坦可用于ESBL/OXA-48-like共生产者。
- 头孢吡肟-他尼硼巴坦可用于KPC和VIM生产者,或作为NDM的二线选择。
- 头孢吡肟-齐德巴坦对MBL活性最有前景,但已出现耐药需谨慎。
研究设计与样本
- 2024年6个月内在法国国家抗菌药物耐药参考中心收集1600株CPE临床分离株。
- 测定三种复方的MIC,所有菌株经全基因组测序完全表征。
主要发现
- KPC生产者中头孢吡肟-恩美唑巴坦敏感率54%,K. pneumoniae ST-307、ST-101和ST-258的MIC较高。
- 头孢吡肟-恩美唑巴坦对90%的OXA-48-like生产者有活性,耐药主要见于Citrobacter freundii ST-22和K. pneumoniae ST-2096。
- 头孢吡肟-他尼硼巴坦对KPC、OXA-48-like、VIM生产者敏感率分别为100%、95%、98%,对NDM为76%。
- 头孢吡肟-他尼硼巴坦耐药主要见于NDM-5生产者,尤其是E. coli ST-140、ST-167和K. pneumoniae ST-147;所有耐药E. coli的PBP3存在4个氨基酸插入。
- 头孢吡肟-齐德巴坦对所有CPE类型活性强,对MBL的MIC值与氨曲南-阿维巴坦相当且低于头孢地尔;耐药株主要为克隆性NDM-14产K. pneumoniae ST-147,未观察到交叉耐药。
临床怎么用
- 对OXA-48-like或ESBL/OXA-48-like共生产者可考虑头孢吡肟-恩美唑巴坦。
- 对KPC或VIM生产者可考虑头孢吡肟-他尼硼巴坦,NDM感染可作二线选择。
- 对MBL生产者头孢吡肟-齐德巴坦活性最有前景,但需警惕已出现的耐药克隆。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Carbapenemase-producing Enterobacterales (CPE) are a public health concern. Developing novel antibiotics, particularly combinations of β-lactam/β-lactamase inhibitors active against carbapenemases, is critical. Three recent combinations, cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam, are among the most promising. To assess the in vitro activity of these three combinations against a collection of recent CPE clinical isolates and to analyse resistance patterns. METHODS: MICs were determined for 1600 CPE isolates collected over 6-month period in 2024 at the French National Reference Centre for Antimicrobial Resistance. All isolates were fully characterized by whole-genome sequencing. RESULTS: Among KPC producers, cefepime-enmetazobactam susceptibility was 54%, with higher MICs in Klebsiella pneumoniae ST-307, ST-101 and ST-258. It was active against 90% of OXA-48-like producers and resistance was primarily observed in Citrobacter freundii ST-22 and K. pneumoniae ST-2096.Cefepime-taniborbactam showed excellent activity against KPC- (100%), OXA-48-like (95%), and VIM producers (98%), but lower efficacy (76%) against NDM producers. Resistance was mainly found in NDM-5 producers, especially E. coli ST-140, ST-167, and K. pneumoniae ST-147. All resistant E. coli displayed a 4-amino-acid insertion in PBP3.Cefepime-zidebactam exhibited strong activity towards all CPE types; regarding MBLs, its low MIC values were comparable to aztreonam-avibactam and lower than cefiderocol. Resistant isolates were mostly clonal NDM-14-producing K. pneumoniae ST-147. No cross-resistance, including with aztreonam-avibactam, was observed. CONCLUSIONS: This study support the use of cefepime-enmetazobactam against ESBL/OXA-48-like co-producers. Cefepime-taniborbactam may be use against KPC and VIM producers and could represent a second-line option for NDM. Cefepime-zidebactam shows the most promising activity against MBLs, although already emerging resistance calls for caution.
引用
- Dutkiewicz M, Jousset AB, de Swardt H, et al. In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales. J Antimicrob Chemother. 2026. PMID: 41424100. doi:10.1093/jac/dkaf440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。